Table 1.
Demographic data between groups.
| S+N+C (n = 11): Group A | N+C (n = 11): Group B | S (n = 11): Group C | Normal (n = 11): Group D | P | Post Hoc P | |
|---|---|---|---|---|---|---|
| Sex | ||||||
| Male | 8 (72.73%) | 6 (54.55%) | 7 (63.64%) | 6 (54.55%) | .788 | |
| Female | 3 (27.27%) | 5 (45.45%) | 4 (36.36%) | 5 (45.45%) | ||
| Age (y) | 22.30 ± 3.30 (18-25) | 19.11 ± 5.34 (14-25) | 21.82 ± 3.31 (18-25) | 17.89 ± 5.37 (13-24) | .143 | |
| Age onset (y) | 14.20 ± 4.51 | 12.08 ± 3.83 | .124 | |||
| Body weight (kg) | 78.48 ± 12.93 | 58.06 ± 18.40 | 52.72 ± 11.06 | 47.57 ± 11.88 | .004* | A/B: .012, A/C: .002, A/D: .001 |
| Body height (cm) | 161.34 ± 5.36 | 156.34 ± 16.69 | 159.82 ± 7.90 | 155.50 ± 19.14 | .964 | |
| BMI (kg/m2) | 28.81 ± 4.47 | 23.53 ± 4.17 | 20.53 ± 3.18 | 19.68 ± 2.34 | .000* | A/B: .003, A/C: .002, A/D: .000, B/D: .004 |
| ESS | 17.70 ± 3.23 | 16.26 ± 4.79 | 5.91 ± 2.21 | 4.09 ± 1.58 | .000* | A/C: .000, A/D: .000, B/C: .005, B/D: .000, C/D: .048 |
| PDSS | 25.40 ± 5.68 | 22.79 ± 4.62 | 10.09 ± 3.30 | 8.55 ± 2.73 | .000* | A/C: .000, A/D: .000, B/C: .005, B/D: .000 |
| VAS | 86.00 ± 16.47 | 83.68 ± 11.25 | 21.82 ± 13.09 | 4.09 ± 3.75 | .000* | A/C: .000, A/D: .000, B/C: .005, B/D: .000, C/D: .000 |
| HLA DQB1 0602 | N = 11 | N = 11 | N = 0 | N = 0 | ||
| NMDA antibody | 1 (+) | (−) | (−) | (−) |
*P < .05. Group A, S+N+C: schizophrenia and narcolepsy type 1, the dual diagnoses group; group B, N+C, narcolepsy type 1, the narcolepsy group; group C, S: schizophrenia, the schizophrenia group; group D, normal: healthy control, the healthy control group. BMI = body mass index, ESS = Epworth Sleepiness Scale, NMDA = N-methyl-d-aspartic acid receptor 1, PDSS = Pediatric Daytime Sleepiness Scale, VAS = visual analog scale.